Prior to her tenure at NHF, Kollet served as the Executive Director of the Bleeding & Clotting Disorders Institute in Peoria IL, a federally recognized Hemophilia Treatment Center (HTC) of Excellence, where she developed and grew an inhouse specialty pharmacy program that became one of the larger programs in the country. Kollet has served on the Hemophilia Alliance Executive Board of Directors, was the chair of the national payer subcommittee, and sat on the Illinois Hemophilia Advisory board.
Kollet and her colleagues on the payer team at the NHF are dedicated to facilitating payer/provider value-based conversations aimed at educating those exposed to high cost claimants about the federally-recognized care management resources that are available, providing transparent tools to analyze where significant savings CAN occur, and identifying data that will enable the development of strategies that will lower costs and improve outcomes.
Hemophilia ranks #12 for highest cost catastrophic claims, #9 for reported high cost claims for stop loss carriers, and #8 of 10 highest cost claims for jumbo employer sponsored health plans. With this in mind, Kollet strongly believes that the stage is set for all parties who share in the cost risks associated with rare chronic disorders to change their current practice of giving away their health care brainpower to those who might have experience with specialty pharmacy dispensation for these chronic rare diseases, without at least entering into dialogue with the experts in managing this patient population. This dialogue should involve the development of plan interventions that do not require a regulatory fix or legislation to be passed so as to begin to find success in lowering overall spend, without risking outcomes.
Learn more about the our Crossroads 2020 Speakers!
An update on #Crossroads2020: https://t.co/iCJhtEk3gf